KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Stake Boosted by Woodline Partners LP

Woodline Partners LP grew its holdings in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 111.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,288,401 shares of the specialty pharmaceutical company's stock after buying an additional 680,148 shares during the period. Woodline Partners LP owned 2.61% of KalVista Pharmaceuticals worth $10,913,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Aquatic Capital Management LLC bought a new stake in shares of KalVista Pharmaceuticals during the fourth quarter valued at approximately $44,000. Tower Research Capital LLC TRC raised its holdings in shares of KalVista Pharmaceuticals by 666.9% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company's stock valued at $54,000 after buying an additional 5,502 shares during the last quarter. Legal & General Group Plc raised its holdings in shares of KalVista Pharmaceuticals by 22.5% during the fourth quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company's stock valued at $69,000 after buying an additional 1,494 shares during the last quarter. Martin Worley Group bought a new stake in shares of KalVista Pharmaceuticals during the fourth quarter valued at approximately $86,000. Finally, China Universal Asset Management Co. Ltd. raised its holdings in shares of KalVista Pharmaceuticals by 24.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company's stock valued at $87,000 after buying an additional 2,043 shares during the last quarter.

Insider Buying and Selling at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, insider Paul K. Audhya sold 2,776 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Monday, May 19th. The shares were sold at an average price of $11.84, for a total transaction of $32,867.84. Following the transaction, the insider now directly owns 106,611 shares in the company, valued at approximately $1,262,274.24. The trade was a 2.54% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Benjamin L. Palleiko sold 3,808 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Monday, May 19th. The stock was sold at an average price of $11.84, for a total transaction of $45,086.72. Following the transaction, the chief executive officer now owns 293,367 shares in the company, valued at approximately $3,473,465.28. The trade was a 1.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 15,399 shares of company stock valued at $182,054. Corporate insiders own 10.50% of the company's stock.

KalVista Pharmaceuticals Stock Performance

Shares of NASDAQ KALV traded up $0.33 during trading on Wednesday, hitting $11.55. The company had a trading volume of 108,934 shares, compared to its average volume of 505,093. The company has a market cap of $573.97 million, a P/E ratio of -3.17 and a beta of 0.05. KalVista Pharmaceuticals, Inc. has a 52 week low of $7.30 and a 52 week high of $15.50. The business's 50-day moving average is $11.93 and its 200 day moving average is $10.45.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. JMP Securities assumed coverage on KalVista Pharmaceuticals in a report on Friday, January 31st. They set an "outperform" rating and a $19.00 target price on the stock. Jones Trading reissued a "buy" rating and set a $30.00 target price on shares of KalVista Pharmaceuticals in a report on Wednesday, March 26th. Needham & Company LLC reissued a "buy" rating and set a $28.00 target price on shares of KalVista Pharmaceuticals in a report on Tuesday, April 8th. HC Wainwright reissued a "buy" rating and set a $20.00 target price on shares of KalVista Pharmaceuticals in a report on Friday, March 14th. Finally, Citizens Jmp raised KalVista Pharmaceuticals to a "strong-buy" rating in a report on Friday, January 31st. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, KalVista Pharmaceuticals currently has an average rating of "Buy" and an average price target of $24.83.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).